Source: Eur Respir J 2014; 43: 295-298
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Woodruff Prescott G., Chatila Wissam, Connett John E., Criner Gerard J., Curtis Jeffrey L., Dransfield Mark T., Han MeiLan K., Lazarus Stephen C., Marchetti Nathaniel, Rogers Thomas J., Scanlon Paul D., Sin Don D., Voelker Helen, Wendt Christine, Albert Richard K.. Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial. Eur Respir J 2014; 43: 295-298

Member's Comments

No comment yet.

Related content which might interest you: Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007 Tumor necrosis factor α in chronic pulmonary diseases of children Source: Eur Respir J 2002; 20: Suppl. 38, 193s Year: 2002 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD Source: Eur Respir J 2007; 30: 810-812 Year: 2007 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Cytokines in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 50S-59S Year: 2001 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 353s Year: 2006 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 Study of tumor necrosis factor family genes in two phenotypes of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 87s Year: 2002 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Mast cell-derived tumour necrosis factor is essential for allergic airway disease Source: Eur Respir J 2008; 31: 773-782 Year: 2008 Tumor necrosis factor-alpha and CD4/CD8 ratio in patients with hypersensitivity pneumonitis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Cytokines in asthma Source: Eur Respir J 2001; 18: 24S-33S Year: 2001 Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers Source: Eur Respir J 2007; 29: 34-41 Year: 2007